Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Silence Therapeutics, listed on Nasdaq as SLN, announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 8:00 a.m. Eastern Time. The presentation will focus on the company's innovative siRNA therapeutics aimed at treating unmet medical needs, including cardiovascular risks and rare hematological diseases. A live webcast will be available on the company’s website, followed by a replay. Silence leverages its proprietary mRNAi GOLD™ platform and collaborates with major industry players.

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the 21st Annual Needham Virtual Healthcare Conference at 8:00 a.m. Eastern Time on Thursday, April 14, 2022.

A live webcast of the presentation will be available on the Investors section of the Silence website at www.silence-therapeutics.com. A replay of the webcast will also be archived on the Company’s website following the conference.

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005200/en/

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc

FAQ

What is Silence Therapeutics presenting at the Needham Virtual Healthcare Conference on April 14, 2022?

Silence Therapeutics will present its innovative siRNA therapeutics for treating significant unmet medical needs, including cardiovascular risks and rare hematological diseases.

Where can I watch Silence Therapeutics' presentation from the Needham Virtual Healthcare Conference?

You can watch the live webcast of Silence Therapeutics' presentation on their website in the Investors section.

What key product candidates does Silence Therapeutics focus on?

Silence Therapeutics focuses on SLN360 for cardiovascular risk and SLN124 for rare hematological diseases.

Which companies is Silence Therapeutics collaborating with?

Silence Therapeutics has ongoing collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma.

What time is Silence Therapeutics' presentation at the Needham Virtual Healthcare Conference?

Silence Therapeutics' presentation is scheduled for 8:00 a.m. Eastern Time on April 14, 2022.